GSK1120212 was a potent MEK inhibitor in our GBM cells, but previous studies have shown that it does not accumulate in the brain (Gilmartin et al., 2011); therefore, we used PD0325901 for in vivo evaluation. Here, MAP2K7 is linked to glioblastoma.